

# Paul F Robbins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2998851/publications.pdf>

Version: 2024-02-01

80  
papers

24,619  
citations

36271

51  
h-index

85498

71  
g-index

82  
all docs

82  
docs citations

82  
times ranked

19320  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes. <i>Science</i> , 2002, 298, 850-854.	6.0	2,598
2	Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 4550-4557.	3.2	1,823
3	Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. <i>Science</i> , 2014, 344, 641-645.	6.0	1,460
4	Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. <i>Journal of Clinical Oncology</i> , 2011, 29, 917-924.	0.8	1,427
5	Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. <i>Journal of Clinical Oncology</i> , 2008, 26, 5233-5239.	0.8	1,210
6	Stabilization of beta -Catenin by Genetic Defects in Melanoma Cell Lines. <i>Science</i> , 1997, 275, 1790-1792.	6.0	1,181
7	T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 2255-2262.	13.9	1,033
8	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. <i>Nature Medicine</i> , 2013, 19, 747-752.	15.2	979
9	PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. <i>Journal of Clinical Investigation</i> , 2014, 124, 2246-2259.	3.9	892
10	T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. <i>Molecular Therapy</i> , 2011, 19, 620-626.	3.7	857
11	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. <i>Nature Medicine</i> , 2016, 22, 433-438.	15.2	721
12	A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. <i>Clinical Cancer Research</i> , 2015, 21, 1019-1027.	3.2	677
13	Identification of essential genes for cancer immunotherapy. <i>Nature</i> , 2017, 548, 537-542.	13.7	668
14	Immunogenicity of somatic mutations in human gastrointestinal cancers. <i>Science</i> , 2015, 350, 1387-1390.	6.0	639
15	Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. <i>Nature Medicine</i> , 2018, 24, 724-730.	15.2	637
16	Cutting Edge: Persistence of Transferred Lymphocyte Clonotypes Correlates with Cancer Regression in Patients Receiving Cell Transfer Therapy. <i>Journal of Immunology</i> , 2004, 173, 7125-7130.	0.4	442
17	A listing of human tumor antigens recognized by T cells. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 3-15.	2.0	426
18	Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions. <i>Clinical Cancer Research</i> , 2014, 20, 3401-3410.	3.2	364

#	ARTICLE	IF	CITATIONS
19	'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. <i>Nature Immunology</i> , 2017, 18, 255-262.	7.0	361
20	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. <i>Journal of Clinical Investigation</i> , 2015, 125, 3981-3991.	3.9	328
21	Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. <i>Science</i> , 2017, 356, 200-205.	6.0	327
22	Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions. <i>Journal of Immunology</i> , 2008, 180, 6116-6131.	0.4	319
23	Enhanced Antitumor Activity of T Cells Engineered to Express T-Cell Receptors with a Second Disulfide Bond. <i>Cancer Research</i> , 2007, 67, 3898-3903.	0.4	315
24	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. <i>Science</i> , 2020, 370, 1328-1334.	6.0	273
25	Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell Therapy. <i>Journal of Immunotherapy</i> , 2008, 31, 742-751.	1.2	236
26	Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. <i>Journal of Immunotherapy</i> , 2019, 42, 126-135.	1.2	231
27	High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens. <i>Journal of Immunology</i> , 2003, 171, 3287-3295.	0.4	219
28	mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 5976-5988.	3.9	218
29	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. <i>Journal of Clinical Oncology</i> , 2017, 35, 3322-3329.	0.8	204
30	Cancer immunotherapy targeting neoantigens. <i>Seminars in Immunology</i> , 2016, 28, 22-27.	2.7	199
31	Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer Therapy. <i>Journal of Immunotherapy</i> , 2005, 28, 53-62.	1.2	198
32	Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 1109-1114.	3.9	193
33	Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers. <i>Cancer Discovery</i> , 2019, 9, 1022-1035.	7.7	184
34	TIL therapy broadens the tumor-reactive CD8 <sup>+</sup> T cell compartment in melanoma patients. <i>OncImmunity</i> , 2012, 1, 409-418.	2.1	171
35	Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. <i>JCI Insight</i> , 2018, 3, .	2.3	168
36	Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor. <i>Cancer Immunology Research</i> , 2016, 4, 734-743.	1.6	163

#	ARTICLE	IF	CITATIONS
37	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. <i>Clinical Cancer Research</i> , 2017, 23, 2491-2505.	3.2	158
38	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. <i>Science</i> , 2022, 375, 877-884.	6.0	156
39	Tumor-infiltrating human CD4 <sup>+</sup> regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. <i>Science Immunology</i> , 2019, 4, .	5.6	152
40	Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression. <i>Journal of Immunology</i> , 2013, 190, 6034-6042.	0.4	145
41	Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. <i>Nature Communications</i> , 2019, 10, 449.	5.8	118
42	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. <i>Cancer Immunology Research</i> , 2016, 4, 669-678.	1.6	117
43	T-cell Responses to TP53 “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 5562-5573.	3.2	114
44	Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. <i>Journal of Clinical Investigation</i> , 2019, 129, 4992-5004.	3.9	107
45	Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 534-543.	1.6	100
46	Predicting T cell recognition of MHC class I restricted neoepitopes. <i>Oncolmmunology</i> , 2018, 7, e1492508.	2.1	82
47	Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 383-394.	2.0	80
48	An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. <i>Molecular Therapy</i> , 2018, 26, 379-389.	3.7	78
49	Multiple HLA Class II-Restricted Melanocyte Differentiation Antigens Are Recognized by Tumor-Infiltrating Lymphocytes from a Patient with Melanoma. <i>Journal of Immunology</i> , 2002, 169, 6036-6047.	0.4	73
50	Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. <i>Clinical Cancer Research</i> , 2020, 26, 1267-1276.	3.2	69
51	Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes. <i>Journal of Clinical Oncology</i> , 2022, 40, 1741-1754.	0.8	65
52	A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. <i>Cancer Cell</i> , 2022, 40, 479-493.e6.	7.7	64
53	Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy. <i>Clinical Cancer Research</i> , 2014, 20, 331-343.	3.2	55
54	Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. <i>Cancer Immunology Research</i> , 2022, 10, 932-946.	1.6	52

#	ARTICLE	IF	CITATIONS
55	Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. <i>Molecular Therapy</i> , 2016, 24, 1078-1089.	3.7	51
56	Targeting neoantigens for cancer immunotherapy: Table 1.. <i>International Immunology</i> , 2016, 28, 365-370.	1.8	42
57	Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy. <i>Cancer Immunology Research</i> , 2019, 7, 1824-1836.	1.6	40
58	Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 5289-5298.	3.2	39
59	A machine learning model for ranking candidate HLA class I neoantigens based on known neopeptides from multiple human tumor types. <i>Nature Cancer</i> , 2021, 2, 563-574.	5.7	38
60	Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing. , 2021, 9, e002595.		31
61	Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. <i>Human Pathology</i> , 2014, 45, 259-267.	1.1	30
62	Tumor-Infiltrating Lymphocyte Therapy and Neoantigens. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 138-143.	1.0	30
63	Isolation and Characterization of an HLA-DPB1*04:01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. <i>Journal of Immunotherapy</i> , 2016, 39, 191-201.	1.2	27
64	Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4347-4353.	3.2	26
65	Identification and Validation of T-cell Receptors Targeting <i>RAS</i> Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5084-5095.	3.2	26
66	Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells. <i>Journal of Immunotherapy</i> , 2021, 44, 1-8.	1.2	21
67	N-linked carbohydrates in tyrosinase are required for its recognition by human MHC class II-restricted CD4+ T cells. <i>European Journal of Immunology</i> , 2001, 31, 2690-2701.	1.6	20
68	Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-PD-1 Naïve and Experienced Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 3042-3052.	3.2	18
69	Impact of Cysteine Residues on MHC Binding Predictions and Recognition by Tumor-Reactive T Cells. <i>Journal of Immunology</i> , 2020, 205, 539-549.	0.4	14
70	Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma. , 2021, 9, e002882.		13
71	T-Cell Receptor-Transduced T Cells. <i>Cancer Journal (Sudbury, Mass )</i> , 2015, 21, 480-485.	1.0	5
72	Longitudinal Study of Recurrent Metastatic Melanoma Cell Lines Underscores the Individuality of Cancer Biology. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1389-1396.	0.3	3

#	ARTICLE	IF	CITATIONS
73	Internal Checkpoint Regulates T Cell Neoantigen Reactivity and Susceptibility to PD1 Blockade. SSRN Electronic Journal, 0, , .	0.4	3
74	Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3' untranslated region of TRIT1. Molecular Therapy - Oncolytics, 2014, 1, 14009.	2.0	2
75	Isolation of T cell receptors specifically reactive with mutated tumor associated antigens. , 2014, 2, .		1
76	Helping Tumor Cells To Die. Journal of Immunology, 2013, 190, 1897-1898.	0.4	0
77	Unique neoantigens expressed by melanomas and common epithelial cancers presented by multiple HLA alleles can be efficiently identified utilizing peptide prediction algorithms. , 2015, 3, .		0
78	Preclinical Evaluation Of Engineered T Cells In Multiple Myeloma: Uncovering a Mechanism Of Immune Escape. Blood, 2013, 122, 4205-4205.	0.6	0
79	Immunology of Melanoma. , 2019, , 1-32.		0
80	Immunology of Melanoma. , 2020, , 41-72.		0